

## Wockhardt Hospitals Limited

October 19, 2022

### Ratings

Facilities/Instruments	Amount (₹ crore)	Rating <sup>1</sup>	Rating Action
Long Term / Short Term Bank Facilities	20.00 (Reduced from 50.00)	CARE BB+; Stable / CARE A4+ (Double B Plus; Outlook: Stable/ A Four Plus)	Reaffirmed
<b>Total Bank Facilities</b>	<b>20.00</b> <b>(₹ Twenty Crore Only)</b>		

Details of instruments/facilities in Annexure-1

### Detailed Rationale & Key Rating Drivers

CARE has reaffirmed the ratings of '**CARE BB+; Stable/ CARE A4+**' assigned to the Bank Guarantee facility of Wockhardt Hospitals Limited (WHL). The ratings assigned to bank facility of WHL are constrained by modest profitability and continuous losses at net level in last several years, weak credit metrics, regulatory risk associated with hospitals and competitive nature of industry. However, ratings continue to derive strength from experienced promoters, established brand name, sustainability in revenue growth, strong presence in western India and stabilization of operations across all 6 hospitals.

### Rating Sensitivities

#### Positive Factors - Factors that could lead to positive rating action/upgrade:

- Improvement in occupancy levels resulting in company reporting post tax profits on sustained basis
- Repayment of debt obligations ensuring gearing below 0.25x

#### Negative Factors- Factors that could lead to negative rating action/downgrade:

- Losses at PBILDT level on a sustained basis
- Increase in overall gearing over 1.0x

### Detailed description of the key rating drivers

#### Key Rating Weaknesses

##### Modest profitability and continuance in PAT loss during FY22

During FY22, WHL's profitability continued to remain modest at 8.83% (FY21: 13.00%). The decline in profitability was due to increase in personnel expenses (doctors 'pay-out) and other overhead cost. Employee cost, consultancy, clinical charges, and other overheads stood at 63% of total revenue for FY22 (FY21: 52% of total revenue). Also, major revenue driven by government scheme services continues to impact the company's profitability. Consequently, the net loss had widened to Rs.53.24 crore in FY22 (FY21: net loss of Rs.11.76 crore) owing to decline in absolute PBILDT as well as deferred tax expense of Rs.27.35 crore.

#### Weak credit metrics

WHL's credit metrics continues to remain weak with total debt to PBILDT at 6.04x in FY22 (FY21: 4.66x). This was on account of increase in total debt and decline in PBILDT in FY22. The increase in debt captures in accumulation of interest on Optionally Convertible Debentures (OCD) and Preference Shares. The debt structure of the company comprises of 37% preference shares, 55% Optionally Convertible Debentures (OCD) and 8% lease liability.

#### Empanelled reputed doctors albeit high reliance on scarcely available professionals

The promoters have also ensured that renowned medical practitioners are empaneled with the hospital which will result in gradual increase in occupancy and augment the income in the coming years. However, WHL is highly dependent on the scarcely available doctors and medical practitioners of repute which is inherent to the nature of business. Based on increasing competition and the scarcity of specialists, the ability of the company to have the distinguished and reputed doctors as consultants and surgeon would be a key differentiator.

#### Highly competitive and capital-intensive nature of industry

Hospital industry is a capital-intensive industry with relatively long gestation period. Generally, new hospital takes around 2-3 years' time frame to breakeven at operational level. Establishment, occupancy rate and financial stability in the initial period of operation takes time. Further, the maintenance capex required for the hospital industry also remains high owing to regular replacement of equipment, non-reusable pharmaceutical and surgical products and to update the latest technology. The industry also faces challenges with respect to hiring on-role and/or off-role doctors, nurses and other staff. Hence dependence on human resources is high and is employed and deployed as per requirement. Moreover, the hospital sector is highly

<sup>1</sup>Complete definition of the ratings assigned are available at [www.careedge.in](http://www.careedge.in) and other CARE Ratings Ltd.'s publications

fragmented with few large players in the organized sector and numerous small players in the unorganized sector leading to high level of competition in the business. Thus, differentiating factors like range of services offered, quality of service, pedigree of doctors, success rate in treatment of critical / complex diseases, etc. will be crucial to attract patients and increase occupancy.

### **Regulatory/Event Risk associated with hospitals**

Hospitals operate in a regulated industry. In India, hospitals are governed by various laws such as Indian Medical Council Act 1956, The Clinical Establishments (registration and regulation) Act 2010, Indian Medical Council Regulations 2002 etc. Given the importance of healthcare facilities, Government of India has been taking various steps towards increasing the affordability and coverage of healthcare services in the country by putting price restriction on pharmaceutical entities, medical equipment manufacturers and hospitals services. Various state governments have also implemented the Clinical Practice Establishment Act, bringing in accountability on how hospitals price their cost of services to patient, and penal provisions for violations. Healthcare is a highly sensitive sector where any mistake on a critical case or negligence on part of any doctor and/or staff of the unit can lead to distrust among the masses. Thus, all the healthcare providers need to monitor each case diligently and meticulously to avoid the occurrence of any unforeseen incident which can damage the reputation of a hospital.

### **Key Rating Strengths**

#### **Experienced and resourceful Promoters**

Wockhardt group belongs to Dr Habil F Khorakiwala led Khorakiwala family, which has an established track record of over five decades in pharmaceutical sector with global presence across various therapeutic segments. The group is looked after by Mr Habil F Khorakiwala (Chairman), his daughter Ms. Zahabiya Khorakiwala (Managing Director) and sons Dr Murtaza Khorakiwala and Dr Huzaifa Khorakiwala. The board is supported by professionals with adequate experience in their respective fields.

The promoters of the company have been infusing funds over the past few years in the form of 6% redeemable preference shares and optionally convertible debentures (OCDs) to fund the losses and maintenance capex. Over the past few years, the promoters have infused Rs.122 crore during FY18-FY20 (Rs.27 crore in FY20, Rs.63 crore in FY19 & Rs.32 crores in FY18) in the company. During FY22 and H1FY23, the promoters have not infused any funds as the company was able to support its operations with cash profit of Rs.16.10 crore as on March 31, 2022.

#### **Sustainability in revenue growth**

Though WHL's occupancy remains moderate in FY22 at 45% (FY21: 49%), the ARPOB increased from Rs.29,041 in FY21 to Rs.38,356 in FY22 owing to increased admissions for Covid as well as non-Covid treatments. This led to improvement in turnover to Rs.606.53 crore (PY: Rs.499 crore). During H1FY23, WHL has reported total revenue of Rs.285 crore.

#### **Established operations as a single/multi-specialty hospital**

WHL continues to provide specialized healthcare and surgical solutions to the patients with 24-hours specialists available for the hospital. The facilities provided are technologically advanced to create convenience for their patients such as wireless equipment (first in Asia), vinyl coated OTs to prevent fungal growth and paper less ICU admissions. It has fully equipped state of the art OTs with flat panel digital cath-lab, state-of-the-art ICUs which are seamless vinyl coated to prevent fungal growth and 24x7 central monitored patient beds. They have developed expertise in super specialities such as Cardiology, Cardiothoracic surgery, Orthopaedics, Gastroenterology, Obstetrics & Gynecology, ENT, Ophthalmology, Dentistry, Paediatrics, Urology, General Surgery, Minimal Invasive Surgery, General Medicine, Pulmonology, Critical care and Accident & Emergency. They have also entered a strategic alliance with Partners Medical International in Boston, USA. This exclusive association enables access to Harvard's expertise and clinical acumen in the areas of medical innovation and training.

#### **Strong presence in western India; stabilisation in hospital operations**

WHL continues to manage a chain of six hospitals under the name of 'Wockhardt Hospitals' located across Maharashtra & Gujarat which are located in Mumbai (2 hospitals), Nagpur (2 hospitals), Nashik (1 hospital) and Rajkot (1 hospital). The hospitals in Mumbai are strategically located viz. Mumbai Central (350 beds), Mumbai Suburban-Mira Road (330 beds) and have been operating since September 2014 and October 2014 respectively. Since COD, both hospitals of Mumbai have stabilized its operations. All the hospitals in Mumbai are multi-speciality offering healthcare facilities under various therapeutic segments. Furthermore, both the hospitals in Nagpur are located in the heart of the city and operating since July 2004 and October 2007, respectively. One of the hospitals in Nagpur is single speciality i.e. in cardiology and the other is into multi-speciality offering medical care in various therapeutic segments. According to the management, operations in one of the hospitals in Nagpur were shut down in FY22 as the company is planning to restructure the hospital. However, during this period, the patients from this hospital were transferred to the second hospital in Nagpur. The other hospitals in Nasik and Rajkot are operating with 170 beds and 177 beds, respectively. The hospitals are favourably located as they cater to the cities in which they are located as well as places located in and around the cities. As on March 31, 2022, WHL has operational capacity of 953 beds. With stabilization of operations across all hospitals, WHL's revenue concentration risk is improved significantly. No single hospital contributes more than 40% of total revenue for year ended on March 31, 2022.

#### **Liquidity: Adequate**

WHL's liquidity profile is marked by healthy cash and bank balance of Rs.26.37 crore as on March 31, 2022. In addition to this, the company does not have any fund-based limits and term loan from the lenders. As on October 13, 2022, WHL has free cash and bank balance of ~Rs.19 crore.

## Analytical approach: Standalone

### Applicable Criteria

[Policy on default recognition](#)

[Financial Ratios – Non financial Sector](#)

[Liquidity Analysis of Non-financial sector entities](#)

[Rating Outlook and Credit Watch](#)

[Short Term Instruments](#)

[Hospital](#)

### About the Company

Incorporated in 1991, Wockhardt Hospitals Limited (WHL), formerly known as First Hospitals & Heart Institute Limited, is promoted by Dr Habil Khorakiwala, Chairman, Wockhardt Group. WHL is a part of Wockhardt group of companies which has an established presence in the pharmaceutical sector through its flagship company i.e. 'Wockhardt Limited' & it is which is engaged in manufacturing and marketing of pharmaceuticals, bio-pharmaceutical formulations, and active pharmaceutical ingredients (APIs) and Vaccines.

WHL provides single-specialty and multi-specialty tertiary health care services through its managed chain of six operational hospitals with a total operational capacity of 953 beds as on March 31, 2022. All the hospitals are run, operated and managed by WHL under the brand name "Wockhardt". WHL has more than a decade old relationship with Partners Harvard Medical International (PHMI) which is involved in clinical training and organizational development. Besides, many of the hospitals managed and run by the company are having accreditation of the NABH (National Accreditation Board of Hospitals & Healthcare).

Brief Financials (₹ crore)	March 31, 2021 (A)	March 31, 2022 (A)	H1FY23 (UA)
Total operating income	490.49	606.53	NA
PBILDT	63.77	53.58	NA
PAT	-11.76	-53.24	NA
Overall gearing (times)	0.63	0.77	NA
Interest coverage (times)	1.50	1.16	NA

A: Audited; UA: Unaudited; NA: Not Available

**Status of non-cooperation with previous CRA:** Not applicable

**Any other information:** Not applicable

**Rating History for last three years:** Please refer Annexure-2

**Covenants of rated instrument / facility:** Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

**Complexity level of various instruments rated for this company:** Annexure 4

### Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Non-fund-based - LT/ST-Bank Guarantee		-	-	-	20.00	CARE BB+; Stable / CARE A4+

**Annexure-2: Rating history for the last three years**

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022	Date(s) and Rating(s) assigned in 2020-2021	Date(s) and Rating(s) assigned in 2019-2020
1	Non-fund-based - LT/ ST-Bank Guarantee	LT/ST*	20.00	CARE BB+; Stable / CARE A4+	-	1)CARE BB+; Stable / CARE A4+ (04-Feb-22)	1)CARE A4+ (15-Feb-21)	1)CARE A4+ (19-Feb-20)

\*Long term/Short term.

**Annexure-3: Detailed explanation of the covenants of the rated instruments/facilities- Not applicable****Annexure-4: Complexity level of various instruments rated for this company**

Sr. No.	Name of Instrument	Complexity Level
1	Non-fund-based - LT/ ST-Bank Guarantee	Simple

**Annexure-5: Bank lender details for this company**

To view the lender wise details of bank facilities please [click here](#)

**Note on complexity levels of the rated instruments:** CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

## Contact us

### Media contact

Name: Mradul Mishra  
Phone: +91-22-6754 3596  
E-mail: [mradul.mishra@careedge.in](mailto:mradul.mishra@careedge.in)

### Analyst contact

Name: Soumya Dasgupta  
Phone: +91-22-6754 3456  
E-mail: [soumya.dasgupta@careedge.in](mailto:soumya.dasgupta@careedge.in)

### Relationship contact

Name: Saikat Roy  
Phone: +91-98209 98779  
E-mail: [saikat.roy@careedge.in](mailto:saikat.roy@careedge.in)

### About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

### Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For the detailed Rationale Report and subscription information,  
please visit [www.careedge.in](http://www.careedge.in)**